Want to see JP:7774 full AI Analyst Report?
7774 Stock Chart & Stats
¥575.00
¥0.00(0.00%)
At close: 4:00 PM EST
¥575.00
¥0.00(0.00%)
Day’s Range― - ―
52-Week Range¥448.00 - ¥883.00
Previous CloseN/A
Volume17.40K
Average Volume (3M)51.90K
Market Cap
¥25.34B
Enterprise Value¥23.69B
Total Cash (Recent Filing)¥3.92B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Aug 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.06
Shares Outstanding40,610,200
10 Day Avg. Volume45,190
30 Day Avg. Volume51,896
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)4.75
Price to Sales (P/S)11.09
P/FCF Ratio-43.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)27.9
Revenue Forecast (FY)¥5.05B
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetEffectively no debt and a conservative balance sheet reduce solvency risk and give management time to execute operational fixes. This provides durable optionality to fund R&D, sustain regulatory compliance costs, and support manufacturing scale without imminent refinancing pressure.
Regenerative-medicine Product FocusA focused portfolio in regenerative medicine addresses structural clinical needs (skin, cartilage) with high barriers to entry. Durable demand from clinical use and reimbursement frameworks supports long-term revenue potential if clinical adoption and regulatory compliance continue.
Manufacturing And Services CapabilitiesOwning controlled manufacturing and cell-processing services creates recurring service revenue, enables partner manufacturing contracts, and captures value across development and supply chains. These capabilities support margin recovery as utilization and scale improve.
Bears Say
Worsening ProfitabilityThe company swung from net income in 2024 to substantially larger losses in 2025–2026, signaling structural cost or demand challenges. Persistent operating losses erode retained earnings, reduce reinvestment capacity, and make achieving sustainable margins more difficult without clear operational fixes.
Negative And Deteriorating Cash FlowLarge negative operating and free cash flows indicate rising cash burn and reliance on balance-sheet resources. Over months, this limits the firm's ability to fund R&D, scale manufacturing, or pursue partnerships without external financing, raising long-term dilution or liquidity risk.
Eroding Equity And ReturnsDeclining equity and negative returns on equity reflect accumulated losses consuming capital cushions. A smaller equity base reduces financial flexibility and may constrain investment or credit access, hindering the company's ability to scale manufacturing or support commercialization.
Japan Tissue Engineering Co., Ltd. News
7774 FAQ
What was Japan Tissue Engineering Co., Ltd.’s price range in the past 12 months?
Japan Tissue Engineering Co., Ltd. lowest stock price was ¥448.00 and its highest was ¥883.00 in the past 12 months.
What is Japan Tissue Engineering Co., Ltd.’s market cap?
Japan Tissue Engineering Co., Ltd.’s market cap is ¥25.34B.
When is Japan Tissue Engineering Co., Ltd.’s upcoming earnings report date?
Japan Tissue Engineering Co., Ltd.’s upcoming earnings report date is Aug 04, 2026 which is in 34 days.
How were Japan Tissue Engineering Co., Ltd.’s earnings last quarter?
Japan Tissue Engineering Co., Ltd. released its earnings results on May 01, 2026. The company reported -¥4.39 earnings per share for the quarter, missing the consensus estimate of N/A by -¥4.39.
Is Japan Tissue Engineering Co., Ltd. overvalued?
According to Wall Street analysts Japan Tissue Engineering Co., Ltd.’s price is currently Overvalued.
Does Japan Tissue Engineering Co., Ltd. pay dividends?
Japan Tissue Engineering Co., Ltd. does not currently pay dividends.
What is Japan Tissue Engineering Co., Ltd.’s EPS estimate?
Japan Tissue Engineering Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Japan Tissue Engineering Co., Ltd. have?
Japan Tissue Engineering Co., Ltd. has 40,610,200 shares outstanding.
What happened to Japan Tissue Engineering Co., Ltd.’s price movement after its last earnings report?
Japan Tissue Engineering Co., Ltd. reported an EPS of -¥4.39 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.34%.
Which hedge fund is a major shareholder of Japan Tissue Engineering Co., Ltd.?
Currently, no hedge funds are holding shares in JP:7774
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Japan Tissue Engineering Co., Ltd.
Japan Tissue Engineering Co., Ltd. operates within the regenerative medicine sector in Japan. The company's activities are organized into three core divisions: Regenerative Medicine Product, Regenerative Medicine Outsourcing, and Research and Development Support. It manufactures and delivers autologous cultured tissues, such as epidermis, cartilage, corneal epithelium, and oral mucosal epithelium, to medical institutions for therapeutic applications. The firm also produces other advanced tissue-engineered medical products. Furthermore, Japan Tissue Engineering is involved in the research and development of three-dimensional human cultured tissue models, which are utilized in the development of external-use cosmetics and drugs, as well as for scientific investigations concerning skin and corneal tissues. Additionally, the company provides comprehensive contract development and manufacturing services for regenerative medicine. Established in 1999, Japan Tissue Engineering Co., Ltd. is based in Gamagori, Japan, and functions as a subsidiary of Teijin Limited.